Climb Bio (CLYM) announced the appointments of Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will ...

Sarepta chief commercial officer Bo Cumbo has left to head up gene therapy venture – AavantiBio – with $107 million in backing from his former employer and three high-profile life sciences ...

announced that Bo Cumbo, President and CEO, will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, at 12:30 pm ET. A live webcast of the fireside chat ...

Solid Biosciences CEO Bo Cumbo said: “Three different measurement methodologies showed what we believe to be a potential best ...

Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present on Thursday, April 10, 2025, at 2:15 pm ET. A live webcast of the presentation will be available on the ...

Solid's CEO, Bo Cumbo, emphasized the company's commitment to developing precision therapies for neuromuscular and cardiac diseases. Several presentations will cover various aspects of SGT-003 and ...

A live webcast of the Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent DirectorsWELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio ...

WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its ...

Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.